GRFS
Grifols, S.A.
NASDAQ · Healthcare · Drug Manufacturers - General · ES
$7.80
−1.02%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 7.4B | 7.2B | 7.2B | 6.6B | 6.1B |
| Cost of Revenue | 4.7B | 4.6B | 4.4B | 4.1B | 3.9B |
| Gross Profit | 2.8B | 2.6B | 2.8B | 2.5B | 2.2B |
| Operating Expenses | |||||
| R&D Expense | 410.0M | 358.3M | 384.0M | 395.3M | 361.1M |
| SG&A Expense | 1.1B | 1.0B | 1.1B | 1.3B | 1.1B |
| General & Admin Expense | — | — | 1.1B | 1.3B | 1.1B |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (2.5M) | 13.4M | 74.5M | 40.4M | (37.7M) |
| Total Operating Expenses | 1.5B | 1.4B | 1.6B | 1.7B | 1.4B |
| Cost and Expenses | 6.2B | 6.0B | 6.0B | 5.8B | 5.3B |
| Operating Income (EBIT) | 1.2B | 1.2B | 1.2B | 782.3M | 782.4M |
| Non-Operating | |||||
| Interest Income | — | 32.7M | 48.1M | 62.4M | 33.9M |
| Interest Expense | 536.2M | 600.3M | 773.2M | 516.1M | 444.5M |
| Net Interest Income | (536.2M) | (567.7M) | (725.1M) | (453.6M) | (410.7M) |
| Other Non-Op Income/Expense | (568.6M) | (596.5M) | (748.0M) | (575.3M) | (444.4M) |
| Non-Operating Income (excl Interest) | (68.3M) | (3.8M) | 145.4M | 59.2M | (120.0K) |
| EBT (Pre-Tax Income) | 669.0M | 590.7M | 444.0M | 207.0M | 338.0M |
| Income Tax Expense | 128.6M | 110.5M | 231.2M | 43.3M | 90.1M |
| Bottom Line | |||||
| Net Income | 452.5M | 386.1M | 156.9M | 42.3M | 185.0M |
| Earnings from Cont. Ops | 540.5M | 480.3M | 212.8M | 163.7M | 247.9M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 452.5M | 386.1M | 156.9M | 42.3M | 185.0M |
| Per Share | |||||
| Basic EPS | $0.67 | $0.57 | $0.23 | $0.09 | $0.31 |
| Diluted EPS | $0.67 | $0.57 | $0.23 | $0.09 | $0.31 |
| Revenue Per Share | $10.92 | $10.62 | $10.61 | $9.70 | $8.92 |
| Shares | |||||
| Basic Shares Outstanding | 680.6M | 680.6M | 680.0M | 679.8M | 679.8M |
| Diluted Shares Outstanding | 680.6M | 680.6M | 680.0M | 679.8M | 679.8M |
| Profitability Metrics | |||||
| EBITDA | 1.7B | 1.6B | 1.5B | 1.2B | 1.2B |
| D&A | 442.7M | 432.2M | 437.9M | 446.4M | 411.0M |
| EBIT | 1.3B | 1.2B | 1.0B | 723.1M | 782.6M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026